Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · BridgeBio Oncology Therapeutics, Inc. (BBOT)

BBOT Q2 net loss widens to $56.5 million from $28.4 million a year earlier

Negative Impact 3 of 5 earnings Written later

BridgeBio Oncology Therapeutics (BBOT) reported a second-quarter 2026 net loss of $56.5 million, up from $28.4 million in the same quarter of 2025, as research and development and general and administrative expenses rose. As of June 30, 2026, the company had $344.1 million in cash, cash equivalents and marketable securities, which it says is expected to provide cash runway into 2028.

Key points

  • Net loss of $56.5 million, or $705.20 per share, for Q2 2026, versus $28.4 million, or $566.46 per share, for Q2 2025
  • R&D expenses rose to $49.2 million from $27.4 million, mainly from higher clinical trial and manufacturing costs for BBO-8520, BBO-11818 and BBO-10203
  • G&A expenses rose to $11.0 million from $2.7 million, including standalone operations, the de-SPAC transaction and one-time severance for former executives
  • Cash and marketable securities were $344.1 million at June 30, 2026, down from $425.5 million at December 31, 2025

The filing

CompanyBridgeBio Oncology Therapeutics, Inc. (BBOT)
Form8-K, current report
Filed with the SECAug 11, 2026, 4:07 PM ET
Accession number0001193125-26-344608

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.